Can Panitumumab be used in combination?

Panitumumab can be used in combination. Bevacizumab (Bevacizumab) and panitumumab are human monoclonal antibodies with different targeting antigens, vascular endothelial growth factor and epidermal growth factor receptor. A study shows that bevacizumab and panitumumab combined with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) can be used as second-line treatment for patients with metastatic colorectal cancer.

The study subjects were patients with metastatic colorectal cancer (mCRC) who had failed previous oxaliplatin-based chemotherapy. They were given bevacizumab (3 mg/kg) and panitumumab (3 mg/kg) plus FOLFIRI every other week. During the four-year study, 173 patients were included in the study. The effective rate was 42.3% and the disease control rate was 65.7%. The median progression-free survival was 6.5 months and the median overall survival was 15.4 months. Various adverse events (AEs) were recorded, including known toxicities related to antibody therapy, with an overall grade 3-4 AE rate of 64.5%. The results show that combination therapy with bevacizumab and panitumumab plusFOLFIRI is effective and safe as second-line treatment for patients with metastatic colorectal cancer (mCRC).

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.